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STING agonist promotes CAR T cell trafficking and
persistence in breast cancer
Nuo Xu1,2, Douglas C. Palmer3, Alexander C. Robeson2, Peishun Shou2, Hemamalini Bommiasamy2, Sonia J. Laurie2, Caryn Willis2,
Gianpietro Dotti1,2, Benjamin G. Vincent1,2,4,5,6, Nicholas P. Restifo3, and Jonathan S. Serody1,2,4,6
CAR T therapy targeting solid tumors is restrained by limited infiltration and persistence of those cells in the tumor
microenvironment (TME). Here, we developed approaches to enhance the activity of CAR T cells using an orthotopic model of
locally advanced breast cancer. CAR T cells generated from Th/Tc17 cells given with the STING agonists DMXAA or cGAMP
greatly enhanced tumor control, which was associated with enhanced CAR T cell persistence in the TME. Using single-cell RNA
sequencing, we demonstrate that DMXAA promoted CAR T cell trafficking and persistence, supported by the generation of a
chemokine milieu that promoted CAR T cell recruitment and modulation of the immunosuppressive TME through alterations
in the balance of immune-stimulatory and suppressive myeloid cells. However, sustained tumor regression was accomplished
only with the addition of anti–PD-1 and anti–GR-1 mAb to Th/Tc17 CAR T cell therapy given with STING agonists. This study
provides new approaches to enhance adoptive T cell therapy in solid tumors.
Introduction
Chimeric antigen receptor (CAR) T cells have substantial activity
against CD19-expressing B cell malignancies in humans (Neelapu
et al., 2017; Maude et al., 2018). These receptors fuse the single-
chain variable fragment (scFv) of an antibody specific to a tumor
target with the signaling molecules of an effector T cell. This
provides these cells with the specificity of an antibody and the
effector function of T cells (Gorochov et al., 1992; Gross and
Eshhar 1992).
Treatment of patients with solid tumors using CAR T cell
therapy, however, has been less successful (Slaney et al.,
2017; Tchou et al., 2017; Beatty et al., 2018). Potential bar-
riers to CAR T cell efficacy against solid tumors include the
suboptimal migration and persistence of CAR T cells in the
tumor microenvironment (TME), impaired function medi-
ated by the immunosuppressive TME, and CAR T cell ex-
haustion. Previous work from our group and others has
shown that T helper 17 (Th17) and CD8+ T 17 (Tc17) cells have
enhanced persistence in solid tumors as compared with
conventional Th1 cells (Boni et al., 2008; Paulos et al., 2010).
Whether CAR T cells generated from Th/Tc17 cells are capable
of persisting in the immunosuppressive TME of solid tumors
remains unclear.
Development of an orthotopic immune-competent model to
evaluate CAR T cell therapy
Given the need to understand mechanistically how to enhance
CAR T cell function in solid tumors, we developed second- and
third-generation murine CAR constructs targeting the proto-
oncogene Neu (Fig. 1 A and Fig. S1 A). Second-generation CAR
T cells were generated using the costimulatory domains from
either CD28 (termed LH28z) or CD137 (4-1BB, termed LHBBZ).
Third-generation CAR T cells were generated using both CD28
and CD137 signaling endodomains (LH28BBZ). Neu-specific CAR
T cells were transduced and expanded with IL-7 and IL-15 (7/15
CAR T cells; Fig. 1 B and Fig. S1 B) at an equal ratio of CD4+ to
CD8+ T cells (Fig. S1 C). These cells were functional in vitro, as they
killed Neu-expressing target cells (Fig. 1 C and Fig. S1 D) and re-
leased proinflammatory cytokines only in response to Neu+ tumor
cells (Fig. 1 D). However, we consistently found that the trans-
duction efficiency of the LHBBz construct was inferior to LH28z or
LH28BBBz constructs (Fig. S1 B). Furthermore, both in vitro (Fig.
S1 D) and in vivo (Fig. S1 E) experiments showed inferior antitu-
mor activity of LH28BBz and LHBBz CAR T cells as compared with
LH28z CAR T cells. Given these findings, we focused on enhancing
the function of LH28z CAR T cells for the remainder of this work.
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Figure 1. Th/Tc17 CAR T cells exhibit enhanced early control of tumor growth over 7/15 CAR T cells owing to enhanced persistence in the tumor.
(A) Schematic of the LH28z CAR cassette encoding the scFv (7.16.4), hinge, and transmembrane domain from CD8, and intracellular domains from CD28 and
CD3ζ. (B) Expression of CAR T receptor on transducedmurine 7/15 CD4+ (left) and CD8+ (right) T cells. (C) Representative flow cytometry histograms depicting
viability of Neu+ NT2 tumor cells in vitro after 3 d of coculture with 7/15 CAR T cells. Tumor cells were prelabeled with CFSE and plated before the addition of
CAR T cells at a 1:1 ratio with tumor cells. (D) Intracellular staining illustrating IFN-γ and TNF production by 7/15 CAR T cells after coculture with Neu+ cells or
Neu− 3T3 cells at a 2:1 ratio. (E) Tumor area change (tumor area before therapy subtracted from area after therapy) was determined and compared in FVB-neu
mice that received 7/15 CAR T cells or mock-transduced T cells (Mock Ts). (F) Expression of CAR T receptor on transduced Th17 (left) or Tc17 (right) cells. (G) In
vitro killing of NT2 tumor cells by 7/15 CAR T and Th/Tc17 CAR T cells after overnight culture. (H) Histogram flow plots of IL-17A, TNF, and IFN-γ secretion by
Th/Tc17 CAR T and 7/15 CAR T compared with mock T cells after coculture with Neu+ cells at 3:1 ratio for 6 h. (I) Tumor area change was calculated and
compared in FVB-neu mice that received Th/Tc17 CAR T cells or 7/15 CAR T cells. (J) Detection of CD4+ and CD8+ CAR T cells in spleen or tumor by flow
cytometry 5 d after injection of 7/15 CAR T cells or Th/Tc17 CAR T cells. Data are shown as mean ± SD; *, P < 0.05; **, P < 0.01; significance was determined by
Student’s t test or two-way ANOVA. n ≥ 5 mice per group with data from at least two independent experiments with the presented data pooled.
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We evaluated the antitumor effects of CAR T cells in an or-
thotopic murine breast tumor model of locally advanced disease
in immunocompetent mice (Fig. S1 F). Despite their in vitro
cytolytic function, LH28z 7/15 CAR T cells were not able to
control tumor growth in vivo (Fig. 1 E), even if hosts were
lymphodepleted using irradiation before CART cell infusion (Fig.
S1 G). Combining 7/15 LH28z CAR T cells with an anti–PD-1 mAb
did not improve the outcome (Fig. S1 H) indicating that blocking
the PD-1/PDL-1 pathway is insufficient for tumor control by 7/15
LH28z CAR T cells. Furthermore, very few CAR T cells were
detected in the TME 5 d after treatment (Fig. S1 I), suggesting that
the limited efficacy of 7/15 LH28z CAR T therapy was at least
partly due to poor trafficking and persistence of CAR T cells in
the TME.
Th/Tc17 CAR T cells have enhanced in vivo persistence
Th17 cells and their counterpart Tc17 cells (CD8+ T cells that
express IL-17A) have longer persistence in the TME, in part due
to their better survival in vivo (Boni et al., 2008; Paulos et al.,
2010). To evaluate if Th/Tc17 CAR T cells had better migration
and/or persistence, we generated LH28z Th/Tc17 CAR T cells.
We compared these cells with 7/15 CAR T cells. Transduction
efficacy (Fig. 1 F) and killing activity in vitro (Fig. 1 G) were
comparable. Th/Tc17 CAR T cells released IL-17A and TNF, while
7/15 CAR T cells expressed IFN-γ and TNF when cocultured with
Neu+ tumor cells in vitro (Fig. 1 H).
We next compared the in vivo antitumor effects of Th/Tc17
CAR T cells and 7/15 CAR T cells. Th/Tc17 CAR T cells were su-
perior to 7/15 CAR T cells in controlling tumor growth up to day
5 after infusion (Fig. 1 I). To identify mechanisms associated
with the improved early efficacy of Th/Tc17 CAR T cells, we
isolated tumor-infiltrating lymphocytes from the TME and as-
sessed their phenotype 5 d after therapy. There was a significant
increase in both CD4+ and CD8+ CAR T cells in the tumor and
CD4+ CAR T cells in the spleen of mice receiving Th/Tc17 CAR
T cells compared with the recipients of 7/15 CAR T cells (Fig. 1 J
and Fig. S1 J). However, Th/Tc17 CAR T cells were only modestly
increased in the TME, which may in part explain the lack of
long-term tumor control. Thus, Th/Tc17 CAR T cells exhibit
modestly improved migration/persistence to the TME and im-
proved early tumor control, but this did not lead to a long-term
antitumor response.
The stimulator of IFN genes (STING) agonist DMXAA greatly
enhances CAR T efficacy
Given the short-term efficacy of Th/Tc17 CAR T cells in vivo, we
sought an approach that would further enhance the migration
and persistence of CAR T cells in the TME. Recent studies have
shown a critical role for the STING pathway in generating
“warm” tumors in the setting of checkpoint inhibitor therapy
(Sen et al., 2019). Thus, we evaluated the activity of the STING
agonist, DMXAA, in combination with CAR T cells. Mice were
injected with NT2 tumors, and when tumors reached ∼50 mm2,
mice were given 7/15 or Th/Tc17 CAR T cells with DMXAA,
which was given at a site remote from the tumor. Interestingly,
DMXAA enhanced the persistence of 7/15 CAR T cells in the TME
(Fig. 2 A). However, this was a modest increase in comparison to
the increase when combined with Th/Tc17 CAR T cells. Thus, we
focused on Th/Tc17 CAR T cells. The administration of DMXAA
before Th/Tc17 CAR T cell infusion significantly improved
antitumor efficacy (Fig. 2 B) and overall survival (Fig. 2 C)
compared with mock-transduced T cells or Th/Tc17 CAR
T cells alone.
We performed single-cell transcriptome sequencing (scRNA-
seq) on CD45+ cells isolated from the TME of mice that received
Th/Tc17 CAR Twith or without DMXAA. These evaluations were
performed on day 7 after CAR T cell therapy, a time point at
which we observed the greatest tumor control, and day 10, when
tumors began to regrow (Fig. 2 D). Based on gene expression
profiles, we identified three immune cell populations in the TME
in mice receiving Th/Tc17 CAR T cells with or without DMXAA.
Specifically, on day 7 after therapy, we identified clusters of
T cells, macrophages, and a second myeloid cell cluster that each
showed differential gene expression profiles in the presence or
absence of DMXAA treatment (Fig. 2 E). In addition, we noted a
relative increase in T cells and a relative decrease in regulatory T
(T reg) cells and a subcluster ofmyeloid cells in the TME on day 7
after CAR T cell therapy (Fig. S2, A and B).
The most noticeable difference in the TME in mice receiving
DMXAA was a substantial increase in T cells compared with
animals given Th/Tc17 CAR T cells without DMXAA (Fig. 3 A and
Fig. S2 A). CD8+ T cells infiltrating the TME exhibited two dif-
ferent phenotypes. A subset expressed the transcription factor
rorc and the cytokine il17a (Fig. 3, B and D), consistent with Tc17
cells. Interestingly, DMXAA treatment enhanced the accumu-
lation of T cells that coexpressed the transcription factor tbx21,
the proinflammatory cytokine ifng, the IFN-inducible chemo-
kine receptor cxcr3, and ccr5, a trafficking receptor found on Th1/
Tc1 cells (Fig. 3, B–D; and Fig. S2 C). This expression pattern is
consistent with the presence of proinflammatory Tc1 cells con-
verted from Tc17 cells in the presence of DMXAA. To confirm
that the increase in T cells in mice receiving DMXAA was most
likely due to the expansion of CAR T cells, flow cytometry was
performed to detect CAR T cells in the TME. DMXAA treatment
greatly increased the percentage and number of CAR T cells in
the TME (Fig. 3 E). In addition, we found a strong association
between the number of CD8+ CAR T cells in the TME and tumor
size in mice receiving DMXAA (Fig. 3 F). The flow cytometry
data coupled with the presence of Th/Tc17 cells in the TME,
which are not found in this model without Th/Tc17 CAR T cell
infusion, strongly suggested that the T cells characterized in our
single-cell analysis were CAR T cells. However, as we could not
identify the CAR construct in all of the CAR T cells by single-cell
analysis, we term these probable CAR T cells.
A combination of Tc17 and Th17 cells were necessary for
antitumor efficacy using DMXAA, as Tc17 cells alone were not
effective in tumor control (Fig. S2, D–F). To evaluate the effect of
DMXAA on CD4+ T cells, we performed scRNA-seq of CD4+
T cells with or without DMXAA treatment (Fig. S2 G). Like the
findings with CD8+ T cells, there was an increase in probable
CAR T cells expressing canonical genes for the Th17 phenotype
(rorc) and genes for a cytolytic Th17/Th1 phenotype (tbx21 and
irf4). We also found an increase in the expression of ifng and
chemokine receptor genes found on Th1 cells (cxcr3 and ccr5; Fig.
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Figure 2. Tumor control by Th/Tc17 CAR T cells is enhanced by DMXAA injection owing to altered composition of tumor infiltrating immune cells.
NT2 tumors were orthotopically injected into murine mammary pads. 21 d later, 500 µg of DMXAA was injected at a site distal to the tumor site, followed by
injection of 3 × 106 mock T cells, 7/15 CAR T cells, or Th/Tc17 CAR T cells (CD4+:CD8+ at ∼1:1 ratio). (A) Representative flow cytometry histograms of CAR T
detection in TME (left) and summary of accumulation of CAR T cells (right). (B) Change in tumor area was measured 7 d after treatment. (C) Kaplan–Meier
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S2, H–K). We confirmed our single-cell data using flow cytom-
etry, which demonstrated an increase in the number and per-
centage of CD4+ CAR T cells in the presence of DMXAA (Fig.
S2 L). This increase was associated with control of tumor
growth (Fig. S2 M). To further validate our single-cell tran-
scriptome data, we performed bulk quantitative PCR array
evaluation of the TME. We found increased expression of genes
associated with the Th1 and Th17 pathways in mice receiving
Th/Tc17 CAR T cells and DMXAA treatment (Fig. S3, A and B).
Finally, we demonstrated a critical role for IFN-γ expression by
demonstrating the loss of activity of Th/Tc17 CAR T cell therapy
plus DMXAA in mice that received anti–IFN-γ mAb (Fig. S3 C).
Thus, DMXAA therapy was associated with a change in the
phenotype of Th/Tc17 T cells to a proinflammatory dual Th17-
Th1/Tc17-Tc1 phenotype, which is critical for tumor control.
CAR T cell exhaustion limits in vivo efficacy
LH28z Th/Tc17 CAR T cell therapy given with DMXAA con-
trolled tumor growth for ∼10 d but did not eradicate the tumor.
To investigate the cause of loss of activity of LH28z Th/Tc17 CAR
T cells with DMXAA, we compared scRNA-seq of the TME on
days 7 and 10 after CAR T cell therapy (Fig. S3 D). As early as day
7 after LH28z Tc/Th17 CAR T cell infusion, we found increased
expression level of pccd1 (PD-1), lag3, cd160, and tox by probable
CAR T cells, with decreased expression of tcf7 (Fig. 3, G–I; and
Fig. S3, D and E). To confirm the single-cell data, flow analysis
was performed on CAR T cells in the TME. There was a signif-
icant increase in PD-1–expressing CD4+ and CD8+ T cells on day 7
after Tc/Th17 LH28z CAR T cell treatment compared with mock-
transduced CAR T cells (Fig. S3 F). We found increased ex-
pression of S100A8 and S100A9, which together generate the
protein calprotectin, which has been shown to induce T cell
apoptosis (Ghavami et al., 2010; Wang et al., 2018; Fig. S3 G).
Additionally, we found an increase in cxcl2, which has been as-
sociated with the recruitment of suppressive myeloid cells into
the TME (Fig. 3 J). Overall, there were clear differences in the
expression of specific exhaustion and or functional genes in
T cells 7 or 10 d after DMXAA treatment.
Alteration of myeloid cells in the TME is associated with the
function of DMXAA
DMXAA can modify the function of innate immune cells (Woo
et al., 2014; Corrales et al., 2016). Thus, we evaluated the effects
of the STING agonist on myeloid cells in the TME. Significant
differences were found in the presence of M1-like and M2-like
macrophages, inflammatory-like myeloid cells (iMCs), and
myeloid-derived suppressive cells (MDSCs) in mice treated
with and without DMXAA (Fig. 4, A and B; and Fig. S2 B). There
was a marked decrease in the presence of M2-like macrophages
expressing retnla, mrc1, folr2, and il10 in the TME after treat-
ment with DMXAA (Fig. 4 C and Fig. S4, A–C). This was asso-
ciated with increased expression of genes associated with
M1-like macrophages, including nos2 and inhba. M1-like mac-
rophages had increased expression of chemokines such as cxcl9,
cxcl10, and ccl5, which recruit Th1/Tc1 T cells by binding to
CXCR3- and CCR5-expressing cells (Fig. 4 D and Fig. S4, A–C).
Consistent with the increased expression of ifng in the presence
of DMXAA, macrophages had increased expression of cd274
(PD-L1; Garcia-Diaz et al., 2017; Fig. S4 D). To demonstrate a
critical role in the recruitment of CAR T cells to the TME byM1-
like macrophages increased after DMXAA treatment, liposome
clodronate was used to deplete these cells. M1-like macrophage
depletion reversed the efficacy of DMXAA over the first week
of Th/Tc17 CAR T cell therapy (Fig. 4 E).
A second cluster of myeloid cells was found after treatment
with DMXAA with greatly enhanced expression of the tran-
scription factor batf2, the chemokine ligands cxcl10 and ccl5, and
downstream genes related to inflammatory function (Kanemaru
et al., 2017), including socs1, nos2, and il12a (Fig. 4, F–I; and Fig. S4,
E–G). Additionally, there was reduced expression of apoe, ptgs2
(Cox2), and areg and (Fig. S4, H–J) a gene expression profile
consistent with MDSC-like cells. Thus, DMXAA was able to
modulate the expression of genes associated with enhanced
antitumor efficacy and to decrease the presence of protumori-
genic myeloid cells.
To characterize the TME immediately before tumor growth,
we evaluated myeloid cell subsets on day 10 after Th/Tc17 CAR
T cell infusion with DMXAA. As shown in Fig. 4 (J–M), there was
a significant change in the TME over this 4-d period, with a
marked increase in the presence of MDSC-like cells expressing
ptgs2, areg, and apoe (Fig. S4, J and K). There was a significant
decrease in the presence of batf2-expressing myeloid cells
(Fig. 4, L and M). Thus, the diminished function of LH28z Th/
Tc17 CAR T cells plus DMXAA was strongly associated with the
reestablishment of an immunosuppressive TME.
Targeting CAR T cell exhaustion and immature myeloid cells
enhanced CAR efficacy
Given our data regarding the expression of PD-1 on CAR T cells
and the marked changes in the immunosuppressive nature of
the TME, we evaluated whether targeting these pathways could
enhance the long-term efficacy of LH28z Th/Tc17 CAR T cells
plus DMXAA. To this end, we treated mice with LH28z Th/Tc17
CAR T cells plus DMXAA alongwith anti–PD-1 and anti–GR-1 mAb
therapy (Fig. 5 A). This approach led to significantly improved
overall survival and control of tumor growth compared with
survival curve for the treatment cohorts. End point criteria for sacrifice was a tumor area of ≥200 mm2. (D) Tumor area change 14 d after indicated therapy.
(E) t-SNE analysis of pooled single-cell sequencing data generated from tumor-infiltrating CD45+ immune cells 7 d after receiving Th/Tc17 CAR T cells in the
presence or absence of DMXAA. Data were analyzed by unsupervised clustering, and populations were determined by expression of key markers, including
Cd3e (T cells), Adgre1 (macrophages), and Itgam and/or Itgax (myeloid cells). Right: Further classification of subpopulation between DMXAA-treated (+DMXAA)
and non–DMXAA-treated (−DMXAA) mice and summary data comparing the frequency of indicated cell populations between +DMXAA and −DMXAA animals.
Gating of flow cytometry data used fluorescence minus one controls for each individual experiment. Data are shown as mean ± SD; ns, not significant; *, P <
0.05; **, P < 0.01; ***, P < 0.001; significance was determined by Student’s t test or log-rank Mantel–Cox test when comparing survival. n ≥ 5 mice per group
with data from at least two independent experiments (except for scRNA-seq), with the presented data pooled.
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Figure 3. DMXAA treatment enhances the number and cytotoxicity of Tc17 CAR T cells in the TME, although they eventually become exhausted.
(A) T cell populations were subdivided based on expression of Cd8 and Cd44 (activated CD8 T cells), Cd44 (naive T cells), and Cd4 and Foxp3 (T reg cells). CD8+
T cells were compared between the +DMXAA and −DMXAA treatment groups, and each subpopulation was examined further as described below. (B) t-SNE
Xu et al. Journal of Experimental Medicine 6 of 16
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mice that received CAR T cell therapy with DMXAA and either
anti–PD-1 or anti–GR-1 mAb therapy (Fig. 5, B–D). However,
substantial antitumor activity was found only in mice that re-
ceived CAR T cells plus DMXAA with either anti–PD-1 or
anti–GR-1 mAb therapy (Fig. 5, B and C). There was no anti-
tumor activity in mice that did not receive CAR T cells or
DMXAA (Fig. 5, B and C). Importantly, optimal tumor control
required CAR T cell therapy with DMXAA and anti–PD-1 and
anti–GR-1 mAbs (Fig. 5 D).
To evaluate whether combination therapy with DMXAA and
anti–PD-1 and anti–GR-1 mAbs could also enhance the antitumor
activity of 7/15 CAR T cells, we compared tumor growth in mice
receiving anti–GR-1 and anti–PD-1 mAb with DMXAA and given
either 7/15 or Th/Tc17 CAR T cells. Much greater antitumor
activity was found with the administration of Th/Tc17 CAR
T cells compared with 7/15 CAR T cells when combined with
DMXAA and anti–PD-1 and anti–GR-1 mAbs (Fig. S5, A and B).
Even in the absence of anti–PD-1 and anti–GR-1 therapy, there
was an increase in CAR T cells in the TME (Fig. 2 A), compared
with the spleen (Fig. S5 C) in mice receiving Th/Tc17 CAR T cells
compared with 7/15 CAR T cells. There was much greater pro-
liferation of CD4+ CAR T cells in mice receiving Th/Tc17 com-
pared with 7/15 CAR T cells (Fig. S5 D). For CD8+ CAR T cells, we
found a significant increase in the number of CD8+ central
memory CAR T cells from day 7 to day 12 after infusion in the
TME of mice receiving Th/Tc17 compared with 7/15 CAR T cells,
which were predominantly effector memory T cells on day 7
(Fig. S5, E and F). Differences in the number of effector versus
central memory CAR T cells were supported by the increased
number of Th/Tc17 CAR T cells with a precursor effector phe-
notype (CD127+ and KLRG1−; Fig. S5 G). In conclusion, sustained
tumor regression caused by Th/Tc17 CAR T cells was associated
with enhanced proliferation and expansion of central memory
T cells.
The human STING agonist cGAMP enhances Th/Tc17 CAR
T cell efficacy
Previous studies have shown that DMXAA does not bind to
human STING and thus does not activate the human protein. To
test the effect of a clinically relevant STING agonist in potenti-
ating the antitumor efficacy of Th/Tc17 CAR T cells, we used 2,3-
cGAMP (cGAMP), a STING agonist that binds to both human and
murine STING. cGAMPwas given subcutaneously in a manner
similar to DMXAA in combination with Th/Tc17 CAR T cells.
The administration of cGAMP enhanced the proliferation and
infiltration of Th/Tc17 CAR T cells at the tumor site (Fig. 6 A).
This was associated with a significant decrease in tumor
growth (Fig. 6, B and C) and enhanced survival of mice re-
ceiving Th/Tc17 CAR T cells (Fig. 6 D). While the overall sur-
vival was not significantly different, mice treated with cGAMP
and Th/Tc17 CAR T cells had better tumor control >21 d after
therapy compared with mice receiving DMXAA and Th/Tc17
CAR T cells (Fig. 6, C and D). Thus, a clinically relevant STING
agonist, cGAMP, enhanced the function of Th/Tc17 CAR T cells
in this model.
Efficacy associated with cytokine release–like syndrome
Treatment of mice with Th/Tc17 CAR T cells, DMXAA, and
anti–PD-1 and anti–GR-1 mAbs led to significant tumor control,
with the majority of mice tumor-free 30 d after treatment.
However, we found that most of the mice that received this
therapy, including critically the anti–GR-1 mAb to deplete im-
munosuppressive myeloid cells, exhibited significant weight
loss and hunching consistent with a cytokine release–like syn-
drome (Fig. 7 A). This was correlated with increasedmortality in
these mice (Fig. 7 B). Treatment efficacy correlated with the
development of this syndrome (Fig. 7 C). This toxicity was ob-
served in mice receiving either DMXAA or cGAMP as the STING
agonist (Fig. 7, A and B). To determine a cause for the increased
toxicity in these mice, we evaluated cytokine levels from the
serum of mice receiving Th/Tc17 CAR with DMXAA and
anti–PD-1 ± anti–GR-1 mAb treatment. Significant increases in
CCL2, G-CSF, and IL-6 were found in mice given anti–GR-1 mAb
compared with mice that did not receive anti–GR-1 treatment
(Fig. 7 D). Mice receiving Th/Tc17 CAR T cells with DMXAA and
anti–PD-1 and anti–GR-1 mAbs were then treated with an
anti–IL-6 antibody, which has demonstrated efficacy in the
treatment of cytokine release syndrome (CRS) in human subjects
receiving CAR T cells (Giavridis et al., 2018; Li et al., 2019). Mice
were given anti–IL-6 antibody on day 5 at the onset of weight loss
in animals treated with combination therapy (Fig. 7 B). As shown
in Fig. 7 (E and F), treatment with anti–IL-6 mAb was associated
with improved survival in mice receiving combination therapy
and did not abrogate the antitumor efficacy of combination
therapy (Fig. 7 G).
Discussion
Although CAR T cells targeting CD19 have been successful in
treating patients with B cell malignancies (Neelapu et al., 2017;
plots of CD8+ T cells for Tc17-related genes. (C) t-SNE plots of CD8+ T cells for Tc1-related genes. (D) Violin plots depicting the distribution and change in
expression of genes identified in B and C. (E) Validation of single-cell sequencing data using flow cytometry to detect CD8+ CAR T cells. Representative flow
plots (left) and frequency (middle) and number (right) of CD8+ CAR T cells. (F) Analysis of the correlation between tumor growth and absolute cell number of
CAR-expressing CD8+ T cells/cm2 tumor. (G) Activated or exhausted T cells were selected by unsupervised clustering result of tumor-infiltrating immune cells
from 7 and 10 d after Th/Tc17 CAR+DMXAA therapy and shown as a t-SNE plot. (H) t-SNE plot (left) and violin plot (right) of T cells assessing genes associated
with T cell exhaustion. (I) t-SNE plot (left) and violin plot (right) of T cells for genes associated with T cell effector function. (J) t-SNE plot (left) and violin plot
(right) of T cells for genes associated with chemokine secretion. Data (excluding scRNA-seq) represent one of two independent experiments (n ≥ 5 mice per
group). Single-cell sequencing data represent two to three mice/treatment group, and statistical significance was determined by differential GSA from Partek
flow workstation. *, q < 0.05; **, q < 0.01; ***, q < 0.001; ****, q < 0.0001 in the change of gene expression level. Fold change is +DMXAA versus −DMXAA or 7
versus 10 d. For percentage/number change, please refer to Fig. S2 C. Flow-cytometric analysis was pooled from two independent experiments and is shown as
mean ± SD. Statistical analysis for cytometric analysis was determined by Student’s t test; ***, P < 0.001; ****, P < 0.0001.
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Figure 4. DMXAA reduces the accumulation of suppressive macrophages and enhances the trafficking of T cells in the TME, but this effect is
eventually lost due to the return of immunosuppressive cells. (A) t-SNE plot of macrophage populations identified by unsupervised clustering (Fig. 2),
selected and classified as M1- or M2-like, and compared between mice receiving therapy with or without DMXAA treatment. (B) Heatmap of genes identified in
Xu et al. Journal of Experimental Medicine 8 of 16
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Maude et al., 2018), the clinical activity of CAR T cells in patients
or animal models with solid tumors has been modest (Slaney
et al., 2017; Tchou et al., 2017; Beatty et al., 2018). Using a ra-
tional and sequential approach, we have implemented a com-
binatorial immunotherapy strategy based on CAR T cells
polarized to a Th/Tc17 phenotype, anti–PD-1 mAb, STING ago-
nists DMXAA or c-GAMP, and anti–GR-1 mAb that leads to tumor
eradication in an immunocompetent syngeneic model of breast
cancer. The most compelling finding was the ability of the STING
agonists, DMXAA and c-GAMP, given at a site remote of the
tumor, to promote CAR T cell recruitment and persistence at the
tumor site. To our knowledge, these data are the first to dem-
onstrate the function of a STING agonist in altering the traf-
ficking properties of adoptive T cellular products. Furthermore,
this activity did not require intratumoral injection of the STING
agonist.
A critical aspect of effective CAR T cell therapy is the ability
of the transferred cells to traffic to tumor sites. CAR T cells
expanded ex vivo and infused intravenously in patients home
physiologically to secondary lymphoid organs such as the bone
marrow and lymph nodes, which explains in part the robust
antitumor effects of CAR T cells observed in patients with leu-
kemia, lymphoma, and multiple myeloma (Hunter et al., 2016).
In contrast, T cells do not constitutively traffic to breast tissue.
Th/Tc17 cells have enhanced biodistribution to peripheral tis-
sues as comparedwith Th1 cells, and thismay explain in part our
observation that Th/Th17 CAR T cells showed superior persis-
tence in the tumor compared with IL7/15 CAR T cells (Fig. 2 A
and Fig. S1 J). To further increase CAR T cell accumulation in
solid tumors, engineering processes have been exploited using
tumor-associated chemokine gradients or by modifying the
stiffness of the extracellular matrix (Moon et al., 2011; Caruana
et al., 2015; Adachi et al., 2018). Here, we report that the STING
agonists DMXAA and cGAMP promoted CAR T cell persistence
within the TME. DMXAA treatment led to increased expression
of cxcl9 and cxcl10 by myeloid cells within the TME. These che-
mokines recruit CXCR3-expressing Th/Tc1 T cells. Correlating
with this finding, DMXAA treatment was associated with a
marked increase in the number of CAR T cells through day 10
after therapy. Interestingly, these T cells had an altered phe-
notype, as they did not generate IFN-γ before infusion but ex-
pressed ifng, tbx21, and cxcr3 after therapy with DMXAA. T cells
expressing IL-17A and IFN-γ have been found in other models
to induce significant tissue pathology (Buonocore et al., 2010;
Hirota et al., 2011). Our data using anti–IFN-γ, which led to a
complete loss of the activity of these CAR T cells in vivo, would
support a critical role for the conversion of Th/Tc17 CAR T cells
to a Th/Tc1 phenotype in their antitumor activity in vivo.
The immunocompetent mouse model we developed allowed
us to assess how the myeloid cell compartment affected the
antitumor activity of CAR T cells. We demonstrate that the
persistence of Th/Tc17 CAR T cells in the TME was associated
with enhanced expression of genes associated with M1-like
macrophages and a marked loss of genes associated with M2-
like macrophages and MDSC-like cells. The decrease in batf2-
expressing iMCs was associated with the inability of CAR
T cells to control tumor growth. Thus, these data suggest that
enhancing CAR T cell trafficking and persistence without al-
tering the immunosuppressive TME is unlikely to lead to sig-
nificant sustained antitumor effects in solid tumors (Newick
et al., 2017; De La Rochere et al., 2018).
Th/Tc17 CAR T cell persistence within the TME, which is
promoted by the proinflammatory myeloid switch caused by a
STING agonist, does not prevent exhaustion of CAR T cells,
which requires checkpoint blockade to sustain CAR T cell–
mediated tumor control. Moreover, a rapid influx of immuno-
suppressive monocytic MDSCs within the TME was also
observed and associated with diminished control of tumor
growth. Previous work had shown that CAR T cells specific for
CEA were inhibited by liver myeloid-derived suppressor cells
when given via the portal vein to mice with liver metastasis
(Burga et al., 2015). Here, we found that depletion of MDSC-like
cells, using anti–GR-1 mAb in combination with CAR T cells,
STING agonist, and PD-1 blockade, allowed sustained regression of
the tumor. We observed, however, that the optimal combination
also led to the development of rapid cachexia consistent with a
CRS. Recent work has highlighted the critical role of myeloid cells
in the pathogenesis of CRS (Norelli et al., 2018; Staedtke et al.,
2018; Sterner et al., 2019). Our data suggest that MDSCs, and
perhaps other immunosuppressive myeloid cells, limit the anti-
tumor efficacy of CAR T cells but also attenuate the severity of the
inflammatory reaction. Fully licensing CAR T cells by depleting
MDSCs exacerbated a CRS, which responded to IL-6 blockade, as
observed in patients receiving CAR T cells targeting CD19.
In summary (Fig. 8), we have found that suboptimal traf-
ficking and persistence/expansion of CAR T cells greatly limits
their antitumor activity in an orthotopic model of locally ad-
vanced breast cancer. The STING agonists, DMXAA or cGAMP,
A exhibiting a greater than twofold change in expression following DMXAA treatment, with a significant difference of P < 0.05 (determined by GSA). (C) t-SNE
plot (left) and violin plots (right) showing expression of M2-related genes. (D) t-SNE plot (left) and violin plots (right) showing expression of M1-related genes.
(E) Tumor area before and after 7 d of treatment with Th/Tc17 CAR T and DMXAA therapy after injection of clodronate or control liposomes. (F) t-SNE plot of
myeloid populations identified by unsupervised clustering (Fig. 2), selected and classified as inflammatory myeloid cells or suppressive myeloid cells, and
compared between mice in the presence or absence of DMXAA treatment. (G) Heatmap of genes identified in F exhibiting a greater than twofold change in
expression following DMXAA treatment, with a significant difference of P < 0.05 (determined by GSA). (H) t-SNE plot depicting genes preferentially expressed
in inflammatory myeloid cells. (I) Violin plots showing distribution and change in expression of genes highlighted in H. Myeloid cells from unsupervised
clustering 7 and 10 d after therapy were selected. (J) t-SNE plot of myeloid cells between 7 and 10 d after therapy. (K) Heatmap of proinflammatory or
suppressive genes that exhibited a greater than twofold change in expression following DMXAA treatment, with a significant difference of P < 0.05. (L) t-SNE
plot of myeloid cells illustrating genes associated with the inflammatory and suppressive functions of myeloid cells. (M) Violin plots showing distribution and
change of indicated gene expression in L. *, P < 0.05; significance was determined by Student’s t test. Single-cell sequencing data represent two to three mice/
treatment group. Macrophage depletion assay was done independently twice with representative result shown.
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greatly enhanced the trafficking and persistence of Th/Tc17 CAR
T cells. These data suggest a viable strategy for boosting CAR T
activity in solid tumors, as cGAMP is in clinical trials for the
treatment of patients with cancer (Woo et al., 2014), there are
multiple ongoing clinical trials using approaches to inhibit
MDSCs for patients with malignant disease (Fleming et al.,
2018), and some clinical trials are currently evaluating the
combination of CAR T cells with checkpoint blockade.
Materials and methods
Tumor cell culture
The 3T3 cell line was obtained from ATCC and cultured in
DMEM (Gibco) supplemented with 10% FBS (Gemini) and 1%
penicillin/streptomycin (Pen/Strep; Invitrogen). 3T3-Neu and
NT2 tumors have been described (Reilly et al., 2000). 3T3-Neu
cultures were made as described and cultured with the addition
of 0.3 µM methotrexate. NT2 cells (passage 6) were cultured in
RPMI-1640 (Gibco) supplementedwith 20% FBS, 2mML-glutamine
(Invitrogen), 12 mM Hepes (Invitrogen), 0.1 mM nonessential
amino acid (Invitrogen), 1 mM sodium pyruvate (Invitrogen),
1% Pen/Strep, 50 µM 2-mercaptoethanol (Invitrogen), and 0.2
U/ml Novolin R-insulin (Novo Nordisk). The virus encoding the
LH28z CAR was cultured in PLAT-E cells from Cell Biolabs in
DMEM supplemented with 10% FBS and 1% Pen/Strep. All cells
used for the generation of the CAR constructs were used within
three passages in vitro, and 0.05% trypsin (Invitrogen) was
used for digestion between passages.
Figure 5. DMXAA is required for tumor re-
mission after Th/Tc17 CAR T, DMXAA, anti–PD-1,
and anti-Gr1 treatment. Animals received in-
jections of anti–PD-1 (200 µg/mouse) and anti-
Gr1 (300 µg/mouse) twice weekly, beginning a
day after CAR T injection in additional to therapy
described in Fig. 2 (Th/Tc17 CAR + D + aP + aG).
(A) Schematic describing therapy schedule.
(B) Summary of tumor growth (in area) in the
first 3 wk after CAR T therapy. (C) Change in
tumor area was assessed 7 d after administration
of Th/Tc CAR + triple therapy or in the absence
of DMXAA, anti–PD-1, anti–Gr-1, or CAR T cells
(mock T cells to model the absence of CAR
T cells). (D) Kaplan–Meier survival curve indi-
cating mortality over 100 d for the four treat-
ment groups. Data are shown as mean ± SD; ns,
not significant; *, P < 0.05; **, P < 0.01; ***, P <
0.001; ****, P < 0.0001; significance was de-
termined by Student’s t test or two-way ANOVA
when comparing tumor growth change between
groups or log-rank Mantel–Cox test when com-
paring survival. n ≥ 5 mice per group with the
data from at least two independent experiments,
with the presented data pooled.
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Vector construct
7/15 and Th/Tc17 CARs contain the scFv of LH28z construct
generated from the 7.16.4 antibody. Whole RNA from the 7.16.4
hybridoma was isolated (RNEasy Kit; Qiagen) and made into
cDNA (M-MLV Reverse Transcription kit; Invitrogen). Anti-
body heavy and light chains were cloned with IgH or IgL
primer mix (iRepertoire) and sequenced by Sanger sequenc-
ing (Genewiz). CAR cDNAs were cloned into a construct
containing murine CD8 transmembrane domain and intra-
cellular domain from murine CD28 or 4-1BB and CD3ξ (LH28z
and LHBBz). The CAR construct was then cloned into MSGV
plasmid driven by 59 LTR. The plasmid construct has been
described (Chinnasamy et al., 2010).
Viral construct preparation and transduction
Plasmids encoding CAR (LH28z) and pCL-Eco retrovirus packaging
vector (Novus) were cotransfected into PLAT-E cells using Lipofect-
amine 2000 (Invitrogen). The supernatant from LH28z-transfected
PLAT-E cells was collected after 48 h and stored at −80°C. For T cell
transduction, LH28z, LHBBz, or LH28z/LHBBz virus was plated onto
a retronectin-coated plate (Takara) and incubated at 32°C for 2 h,
followed by the addition of activated T cells. The coculture was spun
at 1,200 g for 90 min and stored at 37°C overnight.
T cell activation and culture
For 7/15 CAR T cells, splenocytes from 8–14-wk-old female FVB/
NJ mice (Jackson Laboratory) were harvested and activated
Figure 6. Tumor control by Th/Tc17 CAR T cells is enhanced by human STING agonist 2,3-cGAMP. NT2 tumors were orthotopically injected into murine
mammary pads. 21 d later, 25 µg of cGAMPwas injected at a site distal to the tumor site, followed by injection of 3 × 106 mock T cells, 7/15 CAR T cells, or Th/Tc17 CAR
T cells (CD4+:CD8+ at∼1:1 ratio). (A) Representative flow cytometry histograms of CAR T cells detection at in the TME (left) and summary of accumulation of CAR T cells
(right). (B) Change in tumor area measured over 7 d after treatment. (C) Tumor area change 21 d after indicated therapy. (D) Kaplan–Meier survival curve for the
treatment cohorts. Endpoint criteria for sacrifice was tumor area of ≥200 mm2. Gating of flow cytometry data used fluorescence minus one controls for each individual
experiment. Data are shown as mean ± SD; ns, not significant; *, P < 0.05; **, P < 0.01; ***, P < 0.001; significance was determined by Student’s t test or log-rank
Mantel–Cox test when comparing survival. n ≥ 5 mice per group with the data from at least two independent experiments, with the presented data pooled.
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using plate-bound anti-CD3 (145-2C11; Invitrogen) and anti-
CD28 mAb (37.51; Invitrogen) and cultured in RPMI-1640 sup-
plemented with 10% FBS, 2 mM L-glutamine, 12 mM Hepes,
0.1 mM nonessential amino acid, 1 mM sodium pyruvate, 1%
Pen/Strep, 50 µM 2-mercaptoethanol, along with the addition of
1 µg/ml IL-7 and IL-15 (Peprotech). 48 h later, T cells were
transduced with retrovirus and cultured for an additional 3 d
with IL-7 and IL-15. For Th/Tc17 CAR T cells, naive CD4+ and
CD8+ T cells were isolated from the spleens of 8–14-wk-old fe-
male FVB/NJ mice (Jackson Laboratory) using murine naive
CD4/CD8 T Cell Isolation Kit (Miltenyi) according to the man-
ufacturer’s instructions. T cells were activated using plate-
bound anti-CD3 and anti-CD28 mAb (Invitrogen). For the first
week, the culture was maintained as described above with the
addition of TGF-β1 (2 ng/ml), IL-1β (10 ng/ml), TNF (20 ng/ml),
IL-6 (30 ng/ml; Peprotech), anti–IFN-γ (R4-6A2, 10 µg/ml; Bio X
Cell), and anti–IL-2 (JES6-5H4, 10 µg/ml; Bio X Cell; Th17 cyto-
kine cocktail). 2 d after activation, T cells were transduced with
retrovirus and kept in culture with Th17 cytokine cocktail for the
rest of the week. During the second week, cultured T cells were
reactivated using plate-bound anti-CD3 and anti-CD28 mAb and
maintained in Th17 cytokine cocktail plus IL-23 (15 ng/ml;
Peprotech).
Murine tumor model
8–12-wk-old female FVB-Neu mice (FVB/N-Tg(MMTVneu) from
Jackson Laboratory were used under a protocol approved by
University of North Carolina Institutional Animal Care and Use
Committee. For tumor inoculation, mice were intradermally
injected with 5 × 104 NT2 tumor cells into an axillary mammary
gland. 21 d later (day 0), 1.5 × 106 CD4+ and 1.5 × 106 CD8+ CAR
T cells were injected intravenously. Tumors were measured
Figure 7. Depletion of myeloid cells with anti-Gr1 during Th/Tc17 CAR + D/cG + aP regimen leads to cytokine release-like syndrome. Mice received
Th/Tc17 CAR + D + P with or without twice-weekly anti–Gr-1 injections after CAR T therapy. (A) Quantification of weight loss as percentage of total change in
body weight following Th/Tc17 CAR + D/cG + P or Th/Tc17 CAR + D/cG + aP + aG. (B) Kaplan–Meier survival curve indicating mortality over 20 d in the
presence or absence of anti–Gr-1 treatment. (C) Change in tumor area 7 d after Th/Tc17 CAR + D + P or Th/Tc17 CAR + D + aP + aG treatment in mice that
survived but lost >10% of their initial weight (CRS-like) compared with mice that eventually died from CRS-like symptoms (severe CRS-like). (D) Serum
cytokine levels of CCL2, mG-CSF, and IL-6 measured 5 d after therapy. (E) Quantification of weight loss as percentage of total change in body weight following
Th/Tc17 CAR + D + aP + aG + aIL-6 or Th/Tc17 CAR + D + aP + aG treatment. (F) Kaplan–Meier survival curve indicating mortality over 20 d in the presence or
absence of anti–IL-6 mAb treatment. (G) Tumor growth change at 14 d after the therapy in the presence or absence of anti–Gr-1 and/or anti–IL-6 mAb. Data
are shown as mean ± SD; ns, not significant; *, P < 0.05; **, P < 0.01; ****, P < 0.0001; significance was determined by Student’s t test and log-rank
Mantel–Cox test when comparing survival. n ≥ 5 mice per group with the data from at least two independent experiments with the presented data pooled.
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twice weekly with calipers, and the tumor area was calculated as
length × width. The change of tumor area was determined by
subtracting the tumor area before CAR T injection from the
value on the day of measurement. Per institutional guidelines,
tumor-bearing mice were sacrificed when the tumor area
reached 200 mm2 or lost >20% of total body weight. For tumor-
bearing animals receiving combination therapy, animals un-
derwent lymphodepletion with 5 Gy of whole-body irradiation
(X-RAD 320; Precision X-Ray) 1 d before CAR T injection. On the
morning of day 0, mice were injected with 500 µg of DMXAA
(Tocris) or 25 µg of 2,3-cGAMP (InvivoGen) distal to the site of
tumor growth, with CAR T cells injected in the afternoon.
Starting 1 d after CAR T infusion, anti–PD-1 (J43; Bio X Cell;
200 µg/mouse), anti–Gr-1 (RB6-8C5; Bio X Cell; 300 µg/mouse),
or anti–IFN-γ (R4-6A2; Bio X Cell; 250 µg/mouse) mAb were
injected i.p. into recipients. For anti–IL-6 treatment, anti–IL-6
(MP5-20F3; Bio X Cell; 200 µg/mouse first dose and 100 µg/
mouse subsesquent doses) was injected i.p. starting 5 d after
therapy and for the next 4 d.
In vivo tumor-infiltrating immune cell isolation
At indicated time points, tumors were bluntly resected, cut into
small pieces, and processed into a single-cell suspension using
gentleMACS Dissociator (Miltenyi). Lymphocyte enrichment
was achieved by isolating cells at the interface of 44% Percoll
(Sigma-Aldrich) in medium and Lympholyte-M (Cedarlane).
Isolated immune cells were stained as described below. The
lymphocyte fraction was not enriched in experiments in which
absolute cell number was determined.
In vivo tumor-infiltrating immune cells isolation for scRNA-seq
analysis
At day 7 or day 10 after CAR T therapy, tumors were bluntly
resected and cut into small pieces and digested using Tumor
Dissociation Kit, mouse (Miltenyi), in gentleMACS Dissociator
(Miltenyi) according to the manufacturer’s instruction. After
digestion, dead and dying cells were magnetically separated
using a Dead Cell Removal Kit (Miltenyi), after which immune
cells were magnetically enriched using CD45 (TIL) MicroBeads
(Miltenyi). Single cells were partitioned using a Chromium
Controller (10x Genomics), and gene expression sequencing li-
braries were generated using Chromium Single Cell 39 Library &
Gel Bead Kit v3 (10x Genomics). The libraries were pooled and
sequenced using an Illumina NovaSeq 6000 (Illumina). Raw
base call files were demultiplexed with Cell Ranger 3.1.0 (10x
Genomics) and bcl2fastq Conversion Software v2.20.0 (Illu-
mina). The output result was for analysis using Partek flow
workstation. Detailed information for single-cell sequencing is
given in Table 1.
scRNA-seq result analysis
Single-cell results from the Cell Ranger output were analyzed
using Partek flow workstation as follows. Single-cell results
from each sample of Cell Ranger output was filtered using a
Figure 8. Model of the activity of CAR T cells against breast cancer. The use of Th/Tc17 CAR T cells with enhanced proliferation and memory status
(intrinsic modification) along with DMXAA/cGAMP to enhance trafficking and reduce immunosuppression in the TME (extrinsic modification) is critical for the
effective antitumor response of CAR T cells against breast cancer (left). CAR T exhaustion (intrinsic resistance) and reversion back to an immunosuppressive
TME state (extrinsic resistance) are associated with loss of CAR T cell function (middle). The addition of anti–PD-1 to overcome exhaustion (intrinsic mod-
ification) and the depletion of suppressive myeloid cells with anti–Gr-1 (extrinsic modification) leads to sustained tumor remission (right).
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single-cell quality assurance/quality control filter to exclude
doublets/multiplets, cells expressing <30 genes per cell, and
dead cells. Processed results were normalized using the recom-
mended methods, including log normalization of gene expres-
sion and scaling to count permillion. Results were filtered out by
feature (gene) not expressed in 99% of samples. Replicate sam-
ples were pooled and clustered with an unsupervised method
based on principle component analysis, using the first 16 prin-
ciple components. Clustered plots were visualized by
t-distributed stochastic neighbor embedding (t-SNE) plot, in
which cells were clustered using shared nearest neighbor.
Populations were determined by expression of key markers,
including Cd3e (T cells), Adgre1 (macrophages), and Itgam and/
or Itgax (myeloid cells), and T cells were further clustered by
expression of Cd8 and Cd44 (activated CD8 T cells), lack of Cd44
(naive T cells), Cd4 and Cd44 (activated CD4 T cells), and
Cd4 and Foxp3 (T reg cells). For comparison, samples from each
treatment group were pooled by mean expression to simulate
bulk RNA-seq and compared using gene-specific analysis (GSA)
directly. Gene hits that reached P < 0.05withmore than 2-fold or
less than −2-fold expression difference were reported and shown
as a heatmap for pooled samples (macrophages and myeloid
cells) or q < 0.05 with 2- or −2-fold expression difference for
nonpooled samples (T cells). Further detailed analysis steps can
be found on the Partek flow page (https://documentation.partek.
com/pages/viewpage.action?pageId=12943422); parameter set-
tings were default unless indicated.
Flow cytometry
Anti-Neu CAR T cells were detected using recombinant Neu/
Her2.Fc fusion protein conjugated with PE (Neu-PE; Creative
Biomart). Antibodies used in in vitro assays included anti–CD45-FITC/
e450 (30-F11; Invitrogen), anti–IFN-γ-APC (XMG1.2; Invitrogen),
anti–TNF-PE-Cy7 (MP6-XT22; Invitrogen), and anti–IL-17A-
PE (eBio17B7; Invitrogen). Tumor-infiltrating immune cells
were detected and analyzed with anti–CD45-FITC, anti–CD3-
e450 (17A2; Invitrogen), anti–CD4-BV510 (GK1.5; BioLegend),
anti–CD8-APC-Cy7 (53-6.7; BD Biosciences), anti–CD44-
PerCP5.5 (IM7; Invitrogen), anti–CD62L-APC (MEL-14; In-
vitrogen), anti–CD11b-BV711 (M1/70; Invitrogen), anti–F4/
80-BV605 (BM8; Invitrogen), anti–Gr-1-Percp5.5 (RB6-8C5;
Invitrogen), anti–PD-1-PE-Cy7 (J43; Invitrogen), anti–CD127-
BV421 (A7R34; BioLegend), and anti–KLGR1-BV605 (2F1; BD
Biosciences). For in vivo intracellular protein staining,
anti–Foxp3-PerCP5.5 (FJK-16S; Invitrogen) and anti–Ki67-APC
(SOLA15; Invitrogen) were used. Dead cells were excluded
with Fixable Viability Stain 700 (BD Biosciences), and Fc re-
ceptors were blocked with Fc block (BD Biosciences). Cell
number was determined using Count Bright Beads (In-
vitrogen). Data were collected using a BD LSR-Fortessa or BD
Canto cytometer (BD Biosciences). Data were analyzed with
FlowJo software (TreeStar).
Flow cytometry–based T cell cytolytic assay
For coculture killing assays, 106 NT2 tumor cells were labeled
with 5 µM CFSE (Invitrogen) and plated in culture medium for
24 h. CAR T, mock-transfected T cells, or no T cells were added
the next day at the indicated ratios and cocultured in T cell
medium without cytokines for 3 d. Supernatant and trypsinized
cells were collected and stained with 7-amino-actinomycin D
(BD Biosciences) and anti-CD45 (30-F11; Invitrogen). Killing was
measured by flow cytometry after gating on CFSE+, 7-amino-
actinomycin D–negative, and CD45− tumor cells and normalized
to groups without T cell addition. For the killing curve, NT2
tumor cells were labeled with CFSE and plated at 105 cells/well
in a 48-well plate. CAR T cells, mock T cells, or no T cells at the
indicated ratios were added 12 h later. Cocultures were main-
tained in T cell medium without cytokines for 18 h, and cell
killing was measured as described above. Percentage tumor lysis
was calculated by subtracting the number of live tumor cells
from 100% and dividing by the total number of live tumor cells
in the group with no T cells added.
Cytokine release assay
5 × 105 3T3 or 3T3-Neu cells were treated with trypsin and
processed into a single-cell suspension before culture with CAR
T ormock T cells at the indicated ratios in T cell mediumwithout
additional cytokine. 5 µg/ml of brefeldin A (BD Biosciences) was
added after the first hour of coculture. Cells were stimulated for
5 h and then pelleted for extracellular staining with anti-CD45,
Table 1. Details regarding tumor single-cell sequencing analysis
DMXAA treatment Tumor area (mm2) Total CD45+ cells Cells for scRNA-seq Cells recovered for analysis
7 d
+ 38.5 550,000 16,000 6,959
+ 45 425,000 16,000 9,842
+ 33.75 225,000 16,000 3,989
− 59.5 162,500 16,000 11,842
− 55.25 212,500 16,000 8,541
− 63 175,000 16,000 8,246
10 d
+ 45 195,000 16,000 8,044
+ 41.25 195,000 16,000 11,786
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followed by fixation and permeabilization using Fix/Perm Kit
(BD Biosciences) according to the manufacturer’s instructions.
Anti–IFN-γ, anti-TNF, and anti–IL-17A were used for intracel-
lular cytokine staining and detected by flow cytometry.
Cytokine measurements
Cell culture supernatants or serum were collected by direct
collection or cardiovascular puncture and stored at −20°C before
use. The level of cytokines was determined by ELISA or mag-
netic Luminex assay according to the manufacturer’s instruc-
tions (R&D Systems). Data were collected using the Lumina-200
System and analyzed with Bio-Plex Manager 6.1 software
(Bio-Rad).
Real-time PCR array
Whole-tumor RNA was isolated using the RNEasy Kit (Qiagen)
and reverse transcribed using RT2 First Strand Kit (Qiagen).
Quantitative RT-PCR was performed according to the manu-
facturer’s instructions with the RT2 Profiler PCR Array Mouse
Th17 Response (PAMM-073ZE-4; Qiagen) and performed on the
QuantStudio 6K (Applied Biosystems). Count threshold values
were determined with ABI software, and data analysis was
performed using the web-based RT2 Profiler PCR Array Data
Analysis v3.5 (Qiagen). Fold-change was normalized to a house-
keeping gene (Gusb).
Online supplemental material
Fig. S1 describes the generation and efficacy of the CAR con-
struct with different intracellular signaling motifs and an en-
hanced in vivo tumor growth control efficacy by Th/Tc17 CAR
T cells compared with 7/15 CAR T cells. Fig. S2 describes scRNA-
seq results in percentages and the gene expression change of
CD4+ T cells in the TME from scRNA-seq. Fig. S3 describes the
change of gene expression in the TME 7 d after DMXAA treat-
ment by RNA microarray and T cells 10 d after DMXAA treat-
ment by scRNA-seq. Fig. S4 describes the scRNA-seq result on
macrophages and myeloid cells on days 7 and 10 after DMXAA
treatment. Fig. S5 reports the in vivo efficacy of 7/15 CAR T cells
after DMXAA, anti-Gr1, and anti–PD-1 therapy and compares it
with Th/Tc17 CAR T cell treatment.
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Figure S1. IL-7/15 cultured CAR T cells fail to control in vitro or in vivo tumor growth control comparedwith Th/Tc17 CAR T cells. (A) Schematic of the
different CAR cassettes encoding the scFv (7.16.4), hinge and transmembrane domain from CD8 and intracellular domains from CD3ζ, 4-1BB, and/or CD28.
(B) Expression of CAR T receptor on IL-7/15 cultured LH28BBz or LHBBz CAR T cells compared with LH28z CAR T cells. (C) Ratio of CD4+:CD8+ CAR T cells
after 6 d of expansion with IL-7 and IL-15. (D) NT2 cells were cocultured with different ratios of indicated CAR T cells for 6 h, and tumor cell ATP activity was
measured. Tumor ATP level indicating death of tumor cells was characterized at different ratios of mock T cells, LH28z, or LH28BBz CAR T cells. (E) Tumor
area change was calculated following the administration of IL-7/15 cultured LHBBz or LH28z CAR T cells (3 × 106 CAR T cells intravenously at 1:1 CD4+:CD8+
ratio) into tumor-bearing mice when the tumor size reached 50 mm2. (F) Schematic of the tumor model in which 5 × 104 NT2 tumor cells were injected
orthotopically into the mammary fat pad at day −21. Mice received 3 × 106 CAR T cells intravenously at 1:1 CD4+:CD8+ ratio at day 0 when the tumor size
reached 50 mm2. (G) Tumor area change was calculated following injection of 7/15 CAR T before lymphopenia induced by 5 Gy total body irradiation.
(H) Tumor area change was calculated following the administration of anti–PD-1 (200 µg/mouse) twice a week following 7/15 CAR T injection. (I) Rep-
resentative flow cytometry histograms show detection of CAR T cells within the tumor 5 d after 7/15 CAR T infusion. (J) Representative flow plots showing
detection of CAR T cells within the tumor or spleen 5 d after 7/15 CAR T or Th/Tc17 CAR T infusion. Data are shown as mean ± SD; ns, not significant;
significance was determined by Student’s t test or two-way ANOVA. Mouse studies used a minimum of five mice per group and represent at least two
independent experiments. Data were shown as either representative batch or pooled.
Xu et al. Journal of Experimental Medicine S2
STING potentiation of CAR T cell therapy https://doi.org/10.1084/jem.20200844
Figure S2. Th17 CAR T cells are indispensable for DMXAA therapeutic efficacy, which enhances the number and cytotoxicity of Th17 CAR T cells in
the TME. (A and B) Tables for the percentage of T cell subsets (A) and macrophage and myeloid cell subsets (B) calculated from scRNA-seq data. (C) Table for
the percentage of CD8+ T cells expressing indicated genes calculated from scRNA-seq data. (D–F) Assessment of CAR expression on tumor-infiltrating T cells
isolated 7 d after therapy by flow cytometry. (D) Determination of change in tumor area 7 d after injection of Tc17 or Th/Tc17 CAR T cells. (E) Assessment of
intratumoral CD8+ CAR T cells was performed 7 d after therapy. (F) Absolute number of CD8+ CAR T cells/mm2 tumor 7 d after therapy. Data in G–Mdata were
derived from the characterization of T cells expressing CD4 from scRNA-seq result. (G) CD4+ T cells were subdivided based on absence of Cd44 (naive T cells),
expression of Cd4 and Cd44 (activated CD4 T cells), Cd4 and Foxp3 (T reg cells). CD4+ T cells were compared between the +DMXAA and −DMXAA treatment
groups, and each subpopulation was examined further as described below. (H) Table for the percentage of CD4+ T cells expressing the indicated genes from the
scRNA-seq data. (I) t-SNE plot of CD4+ T cells for Th17-related genes. (J) t-SNE plot of CD4+ T cells for Th17/Th1-related genes. (K) Violin plot shows the
distribution and change of indicated gene expression in B and C. (L) Validation of single-cell data using flow cytometry to detect CD4+ CAR T cells. (M) Analysis
of the correlation between tumor growth change and absolute cell number of CAR-expressing CD4 T cells/cm2 tumor. Data (excluding scRNA-seq) represent
one of two independent experiments (n ≥ 5 mice per group). Single-cell sequencing data represent three mice/treatment group, with statistical significance
determined by differential GSA with the Partek flowworkstation. *, q < 0.05; **, q < 0.01, in the change of gene expression level. Fold change is +DMXAA versus
−DMXAA. For percentage/number change, please refer to Fig. S2 H. Flow cytometry data were pooled from two independent experiments and shown as mean
± SD. Statistics analysis for cytometric analysis is determined by Student’s t test; *, P < 0.05; **, P < 0.01; ****, P < 0.0001.
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Figure S3. DMXAA treatment enhances IFN-γ–dependent antitumor function of Th/Tc17 CAR T cells, but T cell exhaustion limits the cumulative
beneficial effect of DMXAA on Th/Tc17 CAR T therapy.Mice received Th/Tc17 CAR T cells in the presence or absence of DMXAA therapy. 7 d later, RNA from
tumors was isolated and analyzed by microarray for Th17/Th1 response. (A) Heatmap depicts genes where fold-change was significant, with a threefold
increase. Each column represents an individual mouse. (B) Quantification of significant changes (P < 0.05) in TME for Th17 or Th1 response following DMXAA
treatment. (C) Mice were treated i.p. with anti–IFN-γ (250 µg/mouse) twice a week after Th/Tc17 CAR T therapy. Significance was determined by Student’s
t test or two-way ANOVA. Studies involved at least four mice per independent experiment. Data from C represent two independent experiments with four mice
per group. (D–G) T cell cluster selected based on expression of Cd3e by unsupervised clustering of tumor-infiltrating immune cells from 7 and 10 d after Th/
Tc17 CAR + D therapy. (D) Table shows the percentage of T cells expressing the indicated genes calculated from scRNA-seq data. (E) t-SNE plot (left) and violin
plot (right) of T cells for genes associated with T cell exhaustion. (F) Validation of PD-1 expression using flow-based method to detect high levels of PD-1
expression on T cells from mice receiving Th/Tc17 CAR T or mock T cell therapy. Representative flow cytometry histograms (left); percentage of CAR T (right)
within the CD4 or CD8 T cell group (n = 4/group). (G) t-SNE plot (left) and violin plot (right) of T cells for genes associated with T cell apoptosis. Data (excluding
scRNA-seq) represent one of two independent experiments (n ≥ 5 mice per group). Single-cell sequencing data represent two to three mice/treatment group.
Statistical significance was determined by differential GSA with the Partek flow workstation. *, q < 0.05; **, q < 0.01; ***, q < 0.001; ****, q < 0.0001 in the
change of gene expression level. Fold change is 7 versus 10 d. For percentage/number change, please refer to Fig. S3 D. Flow cytometric analysis is shown as
mean ± SD. Statistics analysis for cytometric analysis was determined by Student’s t test; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
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Figure S4. M2macrophages andmyeloid cells are reduced upon DMXAA treatment, but later replaced by suppressivemyeloid cells.Macrophages and
myeloid cells from day 7 are selected as in Fig. 3 F. (A) Table showing the percentage of macrophages expressing the indicated genes calculated from scRNA-
seq data. (B) t-SNE plot on M1-like (left) and M2-like (right) related genes. (C) Violin plot shows the distribution and change of indicated gene expression in B.
(D) t-SNE and violin plot of cd274 (PD-L1). (E) Table showing the percentage of myeloid cells expressing the indicated gene calculated from scRNA-seq data.
(F) t-SNE plot on genes expressed in iMCs. (G) Violin plot shows the distribution and change of indicated gene expression in F. (H) t-SNE plot of genes
expressed in myeloid-like suppressor cells. (I) Violin plot shows the distribution and change of indicated gene expression in H. Myeloid cells from days 7 and 10 are
selected as in Fig. 3 J. (J) Table showing the percentage of myeloid cells expressing the indicated genes calculated from scRNA-seq data. (K) t-SNE plot (left) and
violin plot (right) of myeloid cells for genes associatedwithmyeloid-like suppressor cells. Single-cell sequencing data represent two to threemice/treatment group.
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Figure S5. Th/Tc17 cells function better than IL-7/15 CAR T cells when combined with a STING agonist, anti–PD-1, and anti–GR-1 mAb therapy.Mice
were treated with anti–GR-1, anti–PD-1, DMXAA, and Th/Tc17 CAR T cells, 7/15 CAR T cells, or mock T cells as described in Fig. S5. (A) Tumor growth in
individual mice receiving therapy. (B) Kaplan–Meier survival curve. (C) Summary of CAR T cell accumulation in the spleen. (D–G)Mice received 7/15 CAR + D +
aP or Th/Tc17 CAR + D + aP treatment. T cells were isolated from the tumor 7 d after therapy and characterized by flow cytometry. (D) Representative plot
(left) and summary graph (right) of Ki67 expression from CD4+ CAR T cells with six to nine mice per group. (E and F) Assessment of the memory phenotype of
CD8+ CAR T cells from the tumor at 7 or 12 d after 7/15 CAR + D + aP or Th/Tc17 CAR + D + aP treatment. (G) Comparison of memory precursor effector cells of
CD8+ CAR T cells within the tumor 7 d after 7/15 CAR + D + aP or Th/Tc17 CAR + D + aP treatment. Data shown as mean ± SD; ns, not significant; *, P < 0.05; **,
P < 0.01; ***, P < 0.001; ****, P < 0.0001, significance was determined by Student’s t test or log-rank Mantel–Cox test comparing survival. Mouse studies used
a minimum of five mice per group and represent at least two independent experiments where data are shown as either representative or pooled.
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